Treatment of HBV–HCV coinfection
Read
10516
Timeswas read the article
1122
Total PDF
9394
Total HTML
Share statistics
array:24 [ "pii" => "S1665268119319726" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)31972-6" "estado" => "S300" "fechaPublicacion" => "2006-01-01" "aid" => "71631" "copyright" => "Fundación Clínica Médica Sur, A.C." "copyrightAnyo" => "2006" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2006;5 Supl 1:S49-52" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 196 "formatos" => array:3 [ "EPUB" => 6 "HTML" => 152 "PDF" => 38 ] ] "itemSiguiente" => array:19 [ "pii" => "S1665268119319738" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)31973-8" "estado" => "S300" "fechaPublicacion" => "2006-01-01" "aid" => "71632" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2006;5 Supl 1:S53-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 38 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 15 "PDF" => 16 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Treatment of hepatitis C virus infection and renal disease" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S53" "paginaFinal" => "S55" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Nahum Méndez-Sánchez" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Nahum" "apellidos" => "Méndez-Sánchez" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119319738?idApp=UINPBA00004N" "url" => "/16652681/00000005000000S1/v1_201906280857/S1665268119319738/v1_201906280857/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1665268119319714" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)31971-4" "estado" => "S300" "fechaPublicacion" => "2006-01-01" "aid" => "71630" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2006;5 Supl 1:S42-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 48 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 22 "PDF" => 19 ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Treatment of HCV and HIV coinfection" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S42" "paginaFinal" => "S48" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "f0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 839 "Ancho" => 978 "Tamanyo" => 61325 ] ] "descripcion" => array:1 [ "en" => "<p id="sp0010" class="elsevierStyleSimplePara elsevierViewall">Algorithm for the duration of treatment of hepatitis C in patients with HCV-HIV coinfection.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Alberto Juárez Navarro" "autores" => array:1 [ 0 => array:2 [ "nombre" => "J. Alberto Juárez" "apellidos" => "Navarro" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119319714?idApp=UINPBA00004N" "url" => "/16652681/00000005000000S1/v1_201906280857/S1665268119319714/v1_201906280857/en/main.assets" ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Treatment of HBV–HCV coinfection" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S49" "paginaFinal" => "S52" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Rocío Torres Ibarra" "autores" => array:1 [ 0 => array:4 [ "nombre" => "Rocío" "apellidos" => "Torres Ibarra" "email" => array:1 [ 0 => "drarociotorres@prodigy.net.mx" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "aff1" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Servicio de Infectología, IMSS Centro Médico la Raza, México, D.F. México" "etiqueta" => "1" "identificador" => "aff1" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "Address for correspondence:" ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="p0005" class="elsevierStylePara elsevierViewall">Hepatitis B and C viruses are the most frequent causes of chronic disease worldwide. Chronic liver disease can progress to cirrhosis and develop into hepatocarcinoma (HCC). Coinfection with both viruses may occur because they share the same transmission routes. Coinfection with hepatitis C virus (HCV) and hepatitis B virus (HBV) is a more serious disease with a higher risk of progression to HCC than HCV infection alone.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="p0010" class="elsevierStylePara elsevierViewall">According to estimates of the World Health Organization (WHO), approximately 350 million people are infected with HBV and 170 million are infected with HCV. The number of HBV–HCV-coinfected patients is unknown, but it is estimated that it is in between 9%-30%, depending on the geographical region. In Western Europe, the frequency of HBV–HCV coinfection is 0.68% in a selected healthy population.</p><p id="p0015" class="elsevierStylePara elsevierViewall">In an Italian study, it was found that the possibility of coinfection is increased with age, being most frequent in patients older than 50 years. At present, there are large trials, therefore the prevalence may be over-or underestimated.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p><p id="p0020" class="elsevierStylePara elsevierViewall">In all patients presenting with a first episode of acute hepatitis, serological studies must be carried out for various hepatotropic viruses, including HBV and HCV. HBV superinfection may exist in patients with HCV and HCV superinfection may exist in patients with HBV. The possibility of coinfection should be considered for patients with chronic HBV or HCV infection who have been exposed to risk factors such as intravenous drug use.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Interaction of hepatitis viruses</span><p id="p0025" class="elsevierStylePara elsevierViewall">Several studies have proved that HBV and HCV interact and affect host immune response. HCV infection may suppress HBV replication, as proved by studies which found low levels of HBV DNA polymerase and reductions in the expression of hepatitis B surface antigen (HB<span class="elsevierStyleInf">s</span>Ag) and hepatitis B core antigen (HB<span class="elsevierStyleInf">c</span>Ag) in the livers of coinfected patients. On the other hand, patients with chronic HBV infection superinfected by HCV may eliminate HB<span class="elsevierStyleInf">e</span>Ag and HB<span class="elsevierStyleInf">s</span>Ag by seroconversion of anti-HB<span class="elsevierStyleInf">e</span> and anti-HB antibodies.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Sheen et al. carried out a longitudinal study of a large population of HBV-infected patients and found that the annual incidence of seroconversion of HB<span class="elsevierStyleInf">s</span>Ag was higher (2.08%) in HCV coinfected patients than in HBV mono-infected patients (0.43%).</p><p id="p0030" class="elsevierStylePara elsevierViewall">Several mechanisms have been proposed for the inhibition of HBV replication by HCV. Shih et al. suggested that the core protein of HCV suppresses HBV. Another study found that the core protein of HCV suppresses the activity of HBV, affecting transcription. This inhibitory effect seems to be most evident in genotype 1 HCV <span class="elsevierStyleItalic">in vitro</span> and <span class="elsevierStyleItalic">in vivo.</span><a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Other authors have reported that HBV may inhibit replication of HCV. The replication of HBV DNA is negatively correlated to HCV RNA levels in coinfected patients. An Italian study showed that HCV RNA was eliminated from 71% of coinfected patients and from 14% of HCV monoinfected patients. HBV replication is associated with high levels of ALT, but HCV replication is not.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="p0035" class="elsevierStylePara elsevierViewall">The foregoing proves either virus may play a dominant roll, as both have the ability to induce seroconversion and eliminate the other. The chronology of infection plays a role in the determination of the dominant virus.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Clinical characteristics</span><p id="p0040" class="elsevierStylePara elsevierViewall">Various immunological profiles for HCV and HBV infections have been described: acute dual viral hepatitis, chronic hepatitis C with hidden coinfection with HBV, and superinfection by either virus. One of these manifestations will prevail, depending on the location.</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">1. Acute dual HBV–HCV hepatitis</span><p id="p0045" class="elsevierStylePara elsevierViewall">In acute infections, HBV and HCV interact in a manner similar to that observed in chronic infections. In 1982, Liaw et al described coinfection caused by accidental puncture of health-care personnel for the first time. These patients presented with acute HCV infection, but diagnosis of HBV infection was delayed by 6 weeks because of the masking effect of HCV. Acute dual HBV–HCV hepatitis can also occur because of blood transfusion. Mimms et al. studied patients with acute infections with both viruses and compared them to patients who were monoinfected by HBV. They observed decreased levels of alanin aminotransferases (ALT), delayed appearance of HBsAg, and a shorter period of HBsAg anti-genemia in coinfected patients than in monoinfected patients, suggesting that HCV suppresses HBV activity.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">2. Hidden hepatitis B</span><p id="p0050" class="elsevierStylePara elsevierViewall">Hidden hepatitis B entity refers to a condition in which patients have low levels of HBV DNA and in whom serological markers of HBV are absent. Liver cirrhosis occurs in 33% of HBV–HCV coinfected patients and in only 19% of HCV carriers with undetectable HBV DNA.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">3. HCV superinfection</span><p id="p0055" class="elsevierStylePara elsevierViewall">HCV superinfection has been described in Asiatic areas in which there is a high prevalence of HBV. This superinfection results in suppression of HBV replication and elimination of HBsAg carriers. After this stage, HCV infection prevails and patients develop chronic hepatitis, a much more severe disease with a much greater risk of fulminant hepatitis and for which the mortality rate is as high as 10%.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">4. HBV superinfection</span><p id="p0060" class="elsevierStylePara elsevierViewall">HBV superinfection is less common in patients with chronic hepatitis caused by HCV. Only two cases have been reported in which there was suppression of HCV and replication of HBV. HBV superinfection is associated with an increased risk of fulminant hepatitis.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">5. Fulminant hepatitis</span><p id="p0065" class="elsevierStylePara elsevierViewall">Chu et al. carried out a study of patients in Taiwan who were hospitalized with acute hepatitis caused by HCV infection. Eleven patients had fulminant hepatitis, 23% of whom had chronic infection by subjacent HBV compared with 2.9% patients without fulminating hepatitis. These findings were confirmed by studies carried out in France and Taiwan.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">6. Chronic hepatitis</span><p id="p0070" class="elsevierStylePara elsevierViewall">Treatment should be considered for patients in whom both HBV DNA and HCV RNA are present, because of the possibility of progression to cirrhosis and decompensated liver disease. It is also possible that inactive HBsAg carriers can exhibit symptoms of active HCV monoinfection. Conversely, an active HBV infection may be present together with inactive HCV infection (HBV DNA-positive, HBeAg-positive, HCV RNA-negative, anti-HCV-positive). Active HBV infection and inactive HCV infection is less common than active HCV infection and inactive HBV infection, which indicates that HCV is suppressed by HBV. Treatment regimens differ according to individual profiles.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">7. Cirrhosis</span><p id="p0075" class="elsevierStylePara elsevierViewall">HBV–HCV coinfected patients have a higher frequency of cirrhosis than subjects with chronic HBV monoinfection (44% vs 21%, respectively) and a higher incidence of decompensated liver disease (24% KS 6%, respectively) than subjects with chronic HBV monoinfection.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">8. Hepatocellular carcinoma</span><p id="p0080" class="elsevierStylePara elsevierViewall">HBV/HCV coinfection increases the risk of hepato-carcinoma. The frequency of hepatocarcinoma is 63% in coinfected patients and 15% in HCV monoinfected patients. Benvegnu et al. reported that the coinfection was an independent predictor of HCC.(1) Of the 290 cirrhosis patients studied, 45% of coinfected patients developed HCC after 10 years, and 16% and 28% of HBV and HCV patients, respectively, developed HCC after 10 years. Another South African study reported that the risk of HCC in coinfected patients was 83 times higher than that in patients monoinfected with either HBV or HCV.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Treatment</span><p id="p0085" class="elsevierStylePara elsevierViewall">Coinfected patients have several profiles of viral replication and immunity, and the disease has various clinical courses. Because of this, identification of prospects for treatment and selection of optimum antiviral therapy is difficult. Guidelines have been established for treatment of chronic HBV and HCV hepatitis.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="p0090" class="elsevierStylePara elsevierViewall">For viral hepatitis B infection, the Asian Pacific Association for the Study of the Liver (APASL), the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) recommend that treatment of patients with:</p><p id="p0095" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="li0005"><li class="elsevierStyleListItem" id="list0005"><span class="elsevierStyleLabel">1.</span><p id="p0100" class="elsevierStylePara elsevierViewall">mild to serious chronic hepatitis,</p></li></ul><ul class="elsevierStyleList" id="li0010"><li class="elsevierStyleListItem" id="list0010"><span class="elsevierStyleLabel">2.</span><p id="p0105" class="elsevierStylePara elsevierViewall">levels of aminotransferases twice normal levels or biopsy evidence of significant liver damage,</p></li></ul><ul class="elsevierStyleList" id="li0015"><li class="elsevierStyleListItem" id="list0015"><span class="elsevierStyleLabel">3.</span><p id="p0110" class="elsevierStylePara elsevierViewall">HBV DNA levels > 105 copies/mL, and</p></li></ul><ul class="elsevierStyleList" id="li0020"><li class="elsevierStyleListItem" id="list0020"><span class="elsevierStyleLabel">4.</span><p id="p0115" class="elsevierStylePara elsevierViewall">HBeAg positivity or HBeAg negativity.</p></li></ul></p><p id="p0120" class="elsevierStylePara elsevierViewall">Interferon alfa-2b, lamivudine, adenovirus, entecavir, and peginterferon alfa-2a. Treatment indications have also been established for patients with chronic HCV infection.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Contraindications</span><p id="p0125" class="elsevierStylePara elsevierViewall">The presence of decompensated liver disease or liver failure in chronic HBV or HCV infections constitutes an indication for liver transplantation. Until now, there was no standard management protocol for subjects coinfected with HBV and HCV. In general, the criteria for treatment of monoinfections may be applied for HBV–HCV coinfections with chronic hepatitis or compensated cirrhosis. The antiviral regime should be chosen based on serological indexes and levels of viremia.</p><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">1. Interferon</span><p id="p0130" class="elsevierStylePara elsevierViewall">Interferon has immunomodulatory, antiviral, and anti-proliferative activities. In chronic HCV infection, combined antiviral therapy with peginterferon and ribavirin results in a sustained viral response (SVR) of up to 56%. In chronic HBV infection, regular interferon is indicated for patients with elevated levels of ALT and HBV DNA, as it results in a SVR of 35% without inducing viral drug resistance. Peginterferon alfa-2a was recently accepted in the USA for treatment of chronic HBV infection.</p><p id="p0135" class="elsevierStylePara elsevierViewall">Interferon is the most studied drug for coinfected patients. The first report on the use of interferon for coinfected patients was published by Burt et al. in 1993 and showed that interferon resulted in a decrease in of HB<span class="elsevierStyleInf">e</span>Ag and a sustained HCV response. In 1995, Ghent et al. compared the effects of treatment with interferon alfa (3 million units three times per week for 6 months) between 16 chronic coinfected hepatitis patients (anti-HCV positive, HCV RNA positive, AgsHB positive, and HBV DNA negative) and patients with HCV alone. Nineteen percent of patients who received interferon alfa had normal ALT levels and sustained virological responses (control group = 21%), and two patients seroconverted to AgsHB negative. This study showed that the use of interferon is indicated when there is no evidence of HBV replication. Weltman et al. treated eight coinfected patients with 3 million units of interferon alfa three times per week for 6 months and obtained similar results. In an Indian study, seven coinfected patients (AgsHB positive, HBV DNA positive, anti-HCV positive, HCV RNA positive) were treated with high doses of interferon alfa-2b (6 million units three times per day for 6 months). After 6 months of treatment, none of the patients was positive for HBV DNA, all were positive for AgeHB, and HCV RNA was absent in 29% (sustained virological response = 29%).</p><p id="p0140" class="elsevierStylePara elsevierViewall">Villa et al. studied 30 patients with coinfection (Ag-sHB positive, anti-HCV positive, HCV RNA positive) who received 6 or 9 million units of interferon alfa three times per week for 6 months. The high dose of interferon was most effective for clearance of HCV RNA (31.2%) and HBV DNA (100%). The level of histological damage was less in patients given the high dose of interferon.</p><p id="p0145" class="elsevierStylePara elsevierViewall">Most patients with inactive hepatitis B and HCV who are HBV DNA positive relapse after interferon treatment and do not exhibit a SVR. There are no studies on the use of peginterferon for treatment of coinfection.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">2. Interferon plus ribavirin</span><p id="p0150" class="elsevierStylePara elsevierViewall">Liu et al. treated 24 patients (AgsHB positive/anti-HCV positive) with interferon alfa-2a (6 million units three times per week for 12 weeks followed by 3 million units three times per week for 12 weeks) and ribavirin (1200 mg daily for 24 weeks). Seventeen patients were positive for HBV DNA and HCV RNA, with an SVR of 43) for HCV RNA clearance vs 60) in control patients with HCV monoinfected, 6 of the 17 patients with detectable baseline HBV DNA disappearing at the end of the treatment remaining negative 24 weeks after the treatment (35%) and sustained biochemical response of 43%</p><p id="p0155" class="elsevierStylePara elsevierViewall">Hung et al. treated 36 patients with coinfection (Ag-sHB positive, anti-HCV positive, HCV RNA positive) with 3 or 5 million units of interferon alfa-2b three times per week and 800-1200 mg ribavirin daily for 24 weeks. The SVR was 69% and the sustained biochemical response was 56%. Two (11%) of the 18 patients with detectable HBV DNA at the beginning of treatment were free of HBV DNA after treatment and 53% patients who were HBV DNA negative at the initiation of treatment experienced reactivation of HBV DNA in week 48 of the follow-up phase.</p><p id="p0160" class="elsevierStylePara elsevierViewall">Chiang et al. administered combined therapy with high doses of interferon-2b (6 million units three times per week for 24 weeks) and ribavirin (1000-1200 mg/day for 24 weeks) to 42 coinfected patients and a group with HCV monoinfection. The SVR was 69% and 67.2% in HCV coinfected and HCV monoinfected patients, respectively. HBV DNA was absent after treatment in five of 16 patients (31%) who were HBV DNA positive at the initiation of treatment. These results prove that combination treatment is effective for coinfected patients, mainly those who have replication of active HCV. However, possible reactivation of HBV infection should be taken into account.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">3. Interferon and lamivudine</span><p id="p0165" class="elsevierStylePara elsevierViewall">Marine et al. treated eight patients (AgeHB positive, HBV DNA positive, HCV RNA positive) with five million units of interferon plus 100 mg of lamivudine daily for 12 months followed by 100 mg per day of lamivudine only for 6 months. AgeHB and HBV DNA were eliminated in three patients (37.5%). ALT concentrations were normalized in four patients (50%) who also had persistent HCV RNA clearance 12 months after treatment (SVR = 50%). The results of this study suggest that lamivudine may be effective for treatment of patients with chronic hepatitis C and active replication of HBV.</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">4. Adefovir and entecavir</span><p id="p0170" class="elsevierStylePara elsevierViewall">There are no published studies on the use of these drugs for patients with coinfection, but they may be useful for treatment of coinfected patients in whom the dominant virus is HBV.</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">5. Liver transplantation</span><p id="p0175" class="elsevierStylePara elsevierViewall">The unit of participant organs systems (UNOS) reported that 14 patients in the USA received transplants because of coinfection with HBV and HCV in 2004 and that 434 transplants were performed on such patients since 1988. However, posttransplantation data were limited.</p><p id="p0180" class="elsevierStylePara elsevierViewall">Serological and virological tests of HBV–HCV coinfected patients are necessary before considering treatment. Identification of the dominant virus is useful for determining the treatment strategy, because treatment can exacerbate liver disease by inducing loss of viral suppression of the dominant virus. All coinfected patients are prospects for therapy provided that they meet the inclusion criteria for treatment of patients with HBV or HCV monoinfection. When HCV infection is the dominant disease, the treatment of choice is interferon plus ribavirin. When HBV infection is the dominant disease, the treatment of choice is interferon with or without lamivudine. Further studies on treatment with adefovir, entecavir, and triple therapy with lamivudine, ribavirin and interferon for coinfected patients are required before recommendations can be made. Further studies are necessary on peginterferon in coinfected patients, even though it is already a standard treatment for HCV or HBV monoinfection.</p></span></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Recommendations of the consensus panel</span><p id="p0185" class="elsevierStylePara elsevierViewall">In patients with HCV-HBV coinfection, which of the two viruses must be treated?</p><p id="p0190" class="elsevierStylePara elsevierViewall">Although consensus was not reached, most panelists (55%) recommended individualizing each case according to the level or replication of the HBV, while the remaining 44% preferred to treat the HCV infection first.</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Evidence quality: 2</span><p id="p0195" class="elsevierStylePara elsevierViewall">What treatment is recommended?</p><p id="p0200" class="elsevierStylePara elsevierViewall">Most members of the panel of consensus recommended combined treatment with pegylated interferon and ribavirin. A minority (22%) preferred triple therapy with pegylated interferon, ribavirin, and a nucleotide analog.</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Evidence quality: 2</span><p id="p0205" class="elsevierStylePara elsevierViewall">What follow-up visits are required for patients with HCV-HBV coinfection?</p><p id="p0210" class="elsevierStylePara elsevierViewall">The frequency and number of follow-up consultations are similar to those required by a HCV monoinfected patient, but departures from this schedule may be required because of individual circumstances.</p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Evidence quality: 3</span><p id="p0215" class="elsevierStylePara elsevierViewall">What criteria should be applied to determine the SVR of these patients?</p><p id="p0220" class="elsevierStylePara elsevierViewall">The panel of consensus considers that the criteria for viral responses in HCV and HBV monoinfected patients should apply.</p></span><p id="p0225" class="elsevierStylePara elsevierViewall">Evidence quality: 2</p></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:9 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Interaction of hepatitis viruses" ] 1 => array:3 [ "identificador" => "sec0010" "titulo" => "Clinical characteristics" "secciones" => array:8 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "1. Acute dual HBV–HCV hepatitis" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "2. Hidden hepatitis B" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "3. HCV superinfection" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "4. HBV superinfection" ] 4 => array:2 [ "identificador" => "sec0035" "titulo" => "5. Fulminant hepatitis" ] 5 => array:2 [ "identificador" => "sec0040" "titulo" => "6. Chronic hepatitis" ] 6 => array:2 [ "identificador" => "sec0045" "titulo" => "7. Cirrhosis" ] 7 => array:2 [ "identificador" => "sec0050" "titulo" => "8. Hepatocellular carcinoma" ] ] ] 2 => array:2 [ "identificador" => "sec0055" "titulo" => "Treatment" ] 3 => array:3 [ "identificador" => "sec0060" "titulo" => "Contraindications" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0065" "titulo" => "1. Interferon" ] 1 => array:2 [ "identificador" => "sec0070" "titulo" => "2. Interferon plus ribavirin" ] 2 => array:2 [ "identificador" => "sec0075" "titulo" => "3. Interferon and lamivudine" ] 3 => array:2 [ "identificador" => "sec0080" "titulo" => "4. Adefovir and entecavir" ] 4 => array:2 [ "identificador" => "sec0085" "titulo" => "5. Liver transplantation" ] ] ] 4 => array:2 [ "identificador" => "sec0090" "titulo" => "Recommendations of the consensus panel" ] 5 => array:2 [ "identificador" => "sec0095" "titulo" => "Evidence quality: 2" ] 6 => array:2 [ "identificador" => "sec0100" "titulo" => "Evidence quality: 2" ] 7 => array:2 [ "identificador" => "sec0105" "titulo" => "Evidence quality: 3" ] 8 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Benvegnu L" 1 => "Fattovich G" 2 => "Noventa F" 3 => "Tremolada F" 4 => "Chemello L" 5 => "Cecchetto A" 6 => "Alberti A" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/1097-0142(19941101)74:9<2442::aid-cncr2820740909>3.0.co;2-#" "Revista" => array:7 [ "tituloSerie" => "Cancer" "fecha" => "1994" "volumen" => "74" "paginaInicial" => "2442" "paginaFinal" => "2448" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7922998" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0732889316303327" "estado" => "S300" "issn" => "07328893" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Natural history and treatment of hepatitis B virus and hepatitis C virus co-infection. Ann Clin Microbiol Antimicrob" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Crockett S.D." 1 => "Keeffe E.B." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Annal of Clinical Microbiology and Antimicrobial" "fecha" => "2005" "volumen" => "4" "paginaInicial" => "1" "paginaFinal" => "12" "itemHostRev" => array:3 [ "pii" => "S1201971210014682" "estado" => "S300" "issn" => "12019712" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis C virus in the setting of HIV or hepatitis B virus co-infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Sterling R.K." 1 => "Sulkowski M.S." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1055/s-2004-832930" "Revista" => array:7 [ "tituloSerie" => "Seminars in Liver Disease" "fecha" => "2004" "volumen" => "24" "numero" => "Suppl.2" "paginaInicial" => "61" "paginaFinal" => "68" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15346248" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Influence of chronic co-infection with hepatitis B and C virus on liver histology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:9 [ 0 => "Sagnelli E" 1 => "Pasquale G" 2 => "Coppola N" 3 => "Scarano F" 4 => "Marrocco C" 5 => "Scolastico C" 6 => "Santantonio T" 7 => "Gentile A" 8 => "Piccinino F" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s15010-004-3080-6" "Revista" => array:6 [ "tituloSerie" => "Infection" "fecha" => "2004" "volumen" => "32" "paginaInicial" => "144" "paginaFinal" => "148" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15188073" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute hepatitis B and C virus co-infection: a virological and clinical study of 3 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Coppola N" 1 => "Marroco C" 2 => "Di Caprio D" 3 => "Coviello G" 4 => "Scolastico C" 5 => "Filipinni P" 6 => "Sagnelli E" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "CID" "fecha" => "2003" "volumen" => "36" "paginaInicial" => "528" "paginaFinal" => "532" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:8 [ 0 => "Urbani S" 1 => "Boni C" 2 => "Amadei B" 3 => "Fisicaro P" 4 => "Cerioni S" 5 => "Valli M.A." 6 => "Missale G" 7 => "Ferrari C" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.20614" "Revista" => array:7 [ "tituloSerie" => "Hepatology" "fecha" => "2005" "volumen" => "41" "paginaInicial" => "826" "paginaFinal" => "831" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15726541" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0195670116305400" "estado" => "S300" "issn" => "01956701" ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Co-infection of hepatitis C virus in patients with chronic hepatitis B infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:9 [ 0 => "Sato S" 1 => "Fujiyama S" 2 => "Tanaka M" 3 => "Yamasaki K" 4 => "Kuramoto I" 5 => "Kawano S" 6 => "Sato T" 7 => "Mizuno K" 8 => "Nonaka S" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "1994" "volumen" => "21" "paginaInicial" => "159" "paginaFinal" => "166" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7527435" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses co-infection in high HBV endemic area" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Fan C-L" 1 => "Wei L" 2 => "Jiang D" 3 => "Chen H-S" 4 => "Gao Y" 5 => "Li R-B" 6 => "Wang Y" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3748/wjg.v9.i9.2012" "Revista" => array:7 [ "tituloSerie" => "World J Gastroenterol" "fecha" => "2003" "volumen" => "9" "numero" => "9" "paginaInicial" => "2012" "paginaFinal" => "2016" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12970896" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Characteristics of patients with dual infection by hepatitis B and C viruses" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "Zarski J.P." 1 => "Bohn B" 2 => "Bastie A" 3 => "Pawlotsky J.M." 4 => "Baud M" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "1998" "volumen" => "28" "paginaInicial" => "27" "paginaFinal" => "33" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9537860" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African Blacks" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Kew M.C." 1 => "Yu M.C." 2 => "Kedda M.A." 3 => "Coppin A" 4 => "Sarkin A" 5 => "Hodkinson J" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "1997" "volumen" => "112" "paginaInicial" => "184" "paginaFinal" => "187" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8978357" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/00000005000000S1/v1_201906280857/S1665268119319726/v1_201906280857/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/16652681/00000005000000S1/v1_201906280857/S1665268119319726/v1_201906280857/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119319726?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 29 | 4 | 33 |
| 2024 October | 253 | 58 | 311 |
| 2024 September | 351 | 57 | 408 |
| 2024 August | 239 | 17 | 256 |
| 2024 July | 297 | 23 | 320 |
| 2024 June | 221 | 16 | 237 |
| 2024 May | 209 | 11 | 220 |
| 2024 April | 205 | 20 | 225 |
| 2024 March | 243 | 9 | 252 |
| 2024 February | 204 | 20 | 224 |
| 2024 January | 275 | 14 | 289 |
| 2023 December | 206 | 15 | 221 |
| 2023 November | 216 | 26 | 242 |
| 2023 October | 209 | 20 | 229 |
| 2023 September | 194 | 13 | 207 |
| 2023 August | 199 | 14 | 213 |
| 2023 July | 168 | 15 | 183 |
| 2023 June | 168 | 9 | 177 |
| 2023 May | 211 | 15 | 226 |
| 2023 April | 201 | 16 | 217 |
| 2023 March | 163 | 12 | 175 |
| 2023 February | 121 | 22 | 143 |
| 2023 January | 88 | 11 | 99 |
| 2022 December | 101 | 10 | 111 |
| 2022 November | 134 | 11 | 145 |
| 2022 October | 130 | 16 | 146 |
| 2022 September | 147 | 18 | 165 |
| 2022 August | 155 | 12 | 167 |
| 2022 July | 110 | 18 | 128 |
| 2022 June | 127 | 20 | 147 |
| 2022 May | 120 | 13 | 133 |
| 2022 April | 126 | 22 | 148 |
| 2022 March | 209 | 17 | 226 |
| 2022 February | 139 | 18 | 157 |
| 2022 January | 137 | 10 | 147 |
| 2021 December | 155 | 24 | 179 |
| 2021 November | 185 | 22 | 207 |
| 2021 October | 179 | 36 | 215 |
| 2021 September | 156 | 30 | 186 |
| 2021 August | 111 | 17 | 128 |
| 2021 July | 166 | 31 | 197 |
| 2021 June | 120 | 11 | 131 |
| 2021 May | 136 | 31 | 167 |
| 2021 April | 314 | 41 | 355 |
| 2021 March | 251 | 33 | 284 |
| 2021 February | 142 | 27 | 169 |
| 2021 January | 145 | 21 | 166 |
| 2020 December | 125 | 20 | 145 |
| 2020 November | 140 | 14 | 154 |
| 2020 October | 78 | 18 | 96 |
| 2020 September | 94 | 11 | 105 |
| 2020 August | 106 | 15 | 121 |
| 2020 July | 79 | 13 | 92 |
| 2020 June | 65 | 11 | 76 |
| 2020 May | 32 | 6 | 38 |
| 2020 April | 69 | 14 | 83 |
| 2020 March | 71 | 11 | 82 |
| 2020 February | 39 | 6 | 45 |
| 2020 January | 37 | 3 | 40 |
| 2019 December | 27 | 5 | 32 |
| 2019 November | 47 | 9 | 56 |
| 2019 October | 14 | 6 | 20 |
| 2019 September | 2 | 0 | 2 |
| 2019 August | 1 | 2 | 3 |
| 2019 July | 1 | 6 | 7 |
| 2019 June | 2 | 6 | 8 |
Show all
